Arrotex Pharmaceuticals would like to advise that the sale and distribution of Anapen® Junior 150 and Anapen® 300 used for the emergency treatment of anaphylaxis, are to cease in Australia.

The decision to discontinue these strengths is due to lack of demand for a second brand of adrenaline autoinjector for the 150mcg and 300mcg strengths. This decision is voluntary and not related to any quality, safety or efficacy issues regarding the products.

Anapen® Junior 150 will continue to be available until end September 2024 and Anapen® 300 until end July 2024. Anapen® Junior 150 and Anapen® 300 are ‘a’ flagged to EpiPen Junior and EpiPen. Patients with prescriptions for either product can be substituted at pharmacy level with appropriate training.

NOTE: Anapen® 500 and Anapen® Trainer devices remain available and Arrotex is committed to the continued supply of Anapen® 500 as the only 500mcg adrenaline autoinjector available on the PBS.

Visit www.anapen.com.au for questions relating to this discontinuation. Alternatively, call Arrotex Medical Information on 1800 195 055.

This notice has been distributed with permission from Amanda Noom, National Anapen Training Manager. 

> VIEW THE FULL DISCONTINUATION NOTICE FROM ARROTEX HERE